lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma

Mostrar otras versiones (1)

Bone and soft-tissue sarcomas are rare and are highly heterogeneous mesenchymal malignancies. It is therefore challenging to acquire the clinical data of patients with specific histological subtypes of sarcoma using large clinical trials, and there is a need to further establish the diagnosis and tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Hideharu, Takahashi, Masanobu, Watanuki, Munenori, Watanabe, Mika, Hiraide, Sakura, Saijo, Ken, Komine, Keigo, Ishioka, Chikashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063340/
https://www.ncbi.nlm.nih.gov/pubmed/33907565
http://dx.doi.org/10.3892/ol.2021.12716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063340/
https://www.ncbi.nlm.nih.gov/pubmed/33907565
http://dx.doi.org/10.3892/ol.2021.12716

Ejemplares similares